Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1975 Feb;34(1):49–53. doi: 10.1136/ard.34.1.49

Influence of tubercle aggregate size on severity of adjuvant arthritis in the rat.

S P Liyanage, H L Currey, B Vernon-Roberts
PMCID: PMC1006344  PMID: 804868

Abstract

Incorporation into Freund's complete adjuvant of tuberculous aggregates smaller than 90 mum in size is essential to produce adjuvant arthritis in the rat, and this correlates with a significantly greater degree of cell-mediated immunity to tuberculous antigens produced by small aggregates (smaller than 90 mum), when compared with large (larger than 90 mum) aggregates. This requirement for small aggregates to render Freund's complete adjuvant arthritogenic is not paralleled by detectable differences in antimycobacterial humoral antibody production nor by a size-dependent requirement for a conventional adjuvant effect.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Currey H. L., Ziff M. Suppression of experimentally induced polyarthritis in the rat by heterologous anti-lymphocyte serum. Lancet. 1966 Oct 22;2(7469):889–891. doi: 10.1016/s0140-6736(66)91984-2. [DOI] [PubMed] [Google Scholar]
  2. Janossy G., Greaves M. F. Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens. Clin Exp Immunol. 1971 Oct;9(4):483–498. [PMC free article] [PubMed] [Google Scholar]
  3. Koga T., Pearson C. M. Immunogenicity and arthritogenicity in the rat of an antigen from Mycobacterium tuberculosis wax D. J Immunol. 1973 Aug;111(2):599–608. [PubMed] [Google Scholar]
  4. Perper R. J., Oronsky A. L., Blancuzzi V. Antibody to mycobacterial antigens in adjuvant arthritis (AA). I. Relationship to disease and delayed hypersensitivity. Arthritis Rheum. 1972 May-Jun;15(3):283–292. doi: 10.1002/art.1780150310. [DOI] [PubMed] [Google Scholar]
  5. Quagliata F., Phillips-Quagliata J. M. Competence of thoracic duct cells in the transfer of adjuvant disease and delayed hypersensitivity. Evidence that mycobacterial components are required for the successful transfer of the disease. Cell Immunol. 1972 Jan;3(1):78–87. doi: 10.1016/0008-8749(72)90228-6. [DOI] [PubMed] [Google Scholar]
  6. Revell P. A., Dean M. F., Vernon-Roberts B., Muir H., Marshall A. H. Inhibition of macrophage migration by a proteoglycan extracted from Kurloff cells of the guinea-pig. Int Arch Allergy Appl Immunol. 1972;43(6):813–825. doi: 10.1159/000230899. [DOI] [PubMed] [Google Scholar]
  7. Vernon-Roberts B., Currey H. L., Perrin J. T and B cells in the blood and synovial fluid of rheumatoid patients. Ann Rheum Dis. 1974 Sep;33(5):430–434. doi: 10.1136/ard.33.5.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. WAKSMAN B. H., PEARSON C. M., SHARP J. T. Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvant. II. Evidence that the disease is a disseminated immunologic response to exogenous antigen. J Immunol. 1960 Oct;85:403–417. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES